ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
11 févr. 2021 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
13 nov. 2020 08h33 HE
|
ContraFect Corporation
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
26 oct. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
14 août 2020 07h30 HE
|
ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
20 juil. 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
17 juin 2020 07h30 HE
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
15 juin 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
26 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
15 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of TerraForm Power, Inc. – TERP
27 sept. 2017 11h00 HE
|
Pomerantz LLP
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed...